FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145694394> ?p ?o ?g. }

• W2145694394 endingPage "132" @default.
• W2145694394 startingPage "127" @default.
• W2145694394 abstract "Background: Weekly cisplatin concurrent chemoradiation is a treatment in locally advanced cervical cancer. However, there are only few reports in Thai women about hematologic toxicities of this treatment. Objectives: To evaluate prevalence of hematologic toxicities and early response accompanying weekly cisplatin concurrent chemoradiation in cervical cancer patients. Methods: Medical records of cervical cancer patients treated between January 2003 to December 2005 were reviewed retrospectively. Patients were treated by weekly cisplatin 40 mg/m 2 accompanying with radiotherapy of total dose 7500-9000 cGy. Design: Retrospective descriptive study Setting: Ubonrajchathani Cancer Center, Ubonrajchathani Results : 89 out of 95 patients diagnosed as locally advanced cervical cancer and treated by weekly cisplatin in concurrent with radiotherapy were eligible and included for analysis. Mean age was 47.5 years (range, 34-71 years). The major histologic types were squamous cell carcinoma (79.8%), and distribution according to International Federation of Gynecology and Obstetrics (FIGO) stage was IB2 19.1%, IIA 6.7%, IIB 38.2%, IIIA 2.2%, IIIB 31.5% and IVA 2.2%, respectively. 80.9% of patients received five or more cycles of weekly cisplatin. Prevalence of hematologic toxicities was 78.7% and grade 3-4 were found in 14.4% of the patients. There were leukopenia 64.0% (9% grade 3-4), neutropenia 40.4% (7.8% grade 3-4), anemia 57.3% (only 1.1% grade 3-4) and no grade 3-4 thrombocytopenia. Only one patient (1.1%) had febrile neutropenia and this was manageable. There was no significant factor associated with clinical response in this study. Clinical response was evaluated. Complete response was 86.5%, partial response was 13.5%. Conclusions : Prevalence of hematologic toxicities accompanying with weekly cisplatin concurrent chemoradiation was 78.7% and grade 3-4 were found in 14.4% of the patients. Hemotologic toxicities were acceptable and managable. Complete clinical response rate was high." @default.
• W2145694394 created "2016-06-24" @default.
• W2145694394 creator A5008220134 @default.
• W2145694394 creator A5017825037 @default.
• W2145694394 creator A5021920544 @default.
• W2145694394 creator A5031896783 @default.
• W2145694394 creator A5053772898 @default.
• W2145694394 creator A5085236950 @default.
• W2145694394 date "2007-01-01" @default.
• W2145694394 modified "2023-09-24" @default.
• W2145694394 title "Hematologic Toxicities of Cisplatin Concurrent Chemoradiation in Cervical cancer at Ubonrajchathani Cancer Center" @default.
• W2145694394 cites W105982404 @default.
• W2145694394 cites W1547809435 @default.
• W2145694394 cites W1935824237 @default.
• W2145694394 cites W1983239071 @default.
• W2145694394 cites W2018047741 @default.
• W2145694394 cites W2047232494 @default.
• W2145694394 cites W2157719711 @default.
• W2145694394 cites W2258076671 @default.
• W2145694394 cites W2314753133 @default.
• W2145694394 cites W2324392028 @default.
• W2145694394 cites W2328935341 @default.
• W2145694394 hasPublicationYear "2007" @default.
• W2145694394 type Work @default.
• W2145694394 sameAs 2145694394 @default.
• W2145694394 citedByCount "1" @default.
• W2145694394 countsByYear W21456943942014 @default.
• W2145694394 crossrefType "journal-article" @default.
• W2145694394 hasAuthorship W2145694394A5008220134 @default.
• W2145694394 hasAuthorship W2145694394A5017825037 @default.
• W2145694394 hasAuthorship W2145694394A5021920544 @default.
• W2145694394 hasAuthorship W2145694394A5031896783 @default.
• W2145694394 hasAuthorship W2145694394A5053772898 @default.
• W2145694394 hasAuthorship W2145694394A5085236950 @default.
• W2145694394 hasConcept C121608353 @default.
• W2145694394 hasConcept C126322002 @default.
• W2145694394 hasConcept C141071460 @default.
• W2145694394 hasConcept C143998085 @default.
• W2145694394 hasConcept C2776694085 @default.
• W2145694394 hasConcept C2777063308 @default.
• W2145694394 hasConcept C2778220009 @default.
• W2145694394 hasConcept C2778239845 @default.
• W2145694394 hasConcept C2778248108 @default.
• W2145694394 hasConcept C2778850193 @default.
• W2145694394 hasConcept C2780873365 @default.
• W2145694394 hasConcept C509974204 @default.
• W2145694394 hasConcept C71924100 @default.
• W2145694394 hasConcept C90924648 @default.
• W2145694394 hasConceptScore W2145694394C121608353 @default.
• W2145694394 hasConceptScore W2145694394C126322002 @default.
• W2145694394 hasConceptScore W2145694394C141071460 @default.
• W2145694394 hasConceptScore W2145694394C143998085 @default.
• W2145694394 hasConceptScore W2145694394C2776694085 @default.
• W2145694394 hasConceptScore W2145694394C2777063308 @default.
• W2145694394 hasConceptScore W2145694394C2778220009 @default.
• W2145694394 hasConceptScore W2145694394C2778239845 @default.
• W2145694394 hasConceptScore W2145694394C2778248108 @default.
• W2145694394 hasConceptScore W2145694394C2778850193 @default.
• W2145694394 hasConceptScore W2145694394C2780873365 @default.
• W2145694394 hasConceptScore W2145694394C509974204 @default.
• W2145694394 hasConceptScore W2145694394C71924100 @default.
• W2145694394 hasConceptScore W2145694394C90924648 @default.
• W2145694394 hasIssue "2" @default.
• W2145694394 hasLocation W21456943941 @default.
• W2145694394 hasOpenAccess W2145694394 @default.
• W2145694394 hasPrimaryLocation W21456943941 @default.
• W2145694394 hasVolume "22" @default.
• W2145694394 isParatext "false" @default.
• W2145694394 isRetracted "false" @default.
• W2145694394 magId "2145694394" @default.
• W2145694394 workType "article" @default.